Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × margetuximab × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Stomach Neoplasms 3 Recurrence 1 Neoplasm Metastasis 1 HER2-positive Breast Cancer 1 Esophageal Neoplasms 1 Breast Cancer Metastatic 1

Interventions

Trastuzumab 29 pyrotinib 15 pertuzumab 15 Docetaxel 13 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 4 neratinib 3 Ado-Trastuzumab Emtansine 3 trastuzumab deruxtecan 2 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03133988 2025-02-14

Margetuximab Expanded Access Program

TerSera Therapeutics LLC

Approved for marketing

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡